NASDAQ · CYTH
Cyclo Therapeutics, Inc.
$0.72$0.00 (0.0%)
Cyclo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.52% below the high.
Loading market information…
NASDAQ · AXDX · USD
Stock price, earnings
Quote as of May 14, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Accelerate Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.37% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Accelerate Diagnostics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in solutions for the rapid diagnosis of critical infections, with operations spanning the United States, Europe, and the Middle East. The company's primary offering is the Accelerate Pheno system, an advanced in vitro diagnostic platform. Paired with its dedicated test kit, the Accelerate PhenoTest, this system facilitates quick identification and antimicrobial susceptibility testing (AST) for pathogens responsible for severe or healthcare-associated infections, encompassing both Gram-positive and Gram-negative organisms. The PhenoTest is specifically designed to yield crucial ID and AST results for patients suspected of bacteremia or fungemia – life-threatening conditions marked by high morbidity and mortality risks. Established in 1982, the company initially operated as Accelr8 Technology Corporation before adopting its current name, Accelerate Diagnostics, Inc., in December 2012. Its corporate headquarters are located in Tucson, Arizona.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $3.00M-12.95% vs estimate |
| Q3 2023 | Nov 9, 2023 | -$0.92+2.13% vs estimate | $3.30M-6.64% vs estimate |
|---|
| Q2 2023 | Aug 10, 2023 | -$2.36-69.24% vs estimate | $2.92M-18.88% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.72$0.00 (0.0%)
Cyclo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.52% below the high.
$2.07+$0.10 (+5.08%)
PAVmed Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.72% below the high.
$0.04-$0.02 (-27.27%)
Impel Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.05% below the high.
$0.51-$0.16 (-23.29%)
Lucy Scientific Discovery Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.99% below the high.
$0.66-$0.21 (-24.02%)
Acorda Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.27% below the high.
$0.07-$0.01 (-6.68%)
Bellicum Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.29% below the high.
$0.02+$0.00 (+27.39%)
BIOLASE, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.97% below the high.
$0.00$0.00 (0.0%)
Infinity Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.15% below the high.
